Notice type: 3rd Party Publications
Problem Or Issue:
Important Safety Information from Janssen Sciences Ireland UC regarding Imbruvica (ibrutinib): New risk minimisation measures, including dose modification recommendations, due to the increased risk for serious cardiac events
Important Safety Information – Imbruvica (ibrutinib)